{"id":13465,"date":"2023-09-05T04:30:00","date_gmt":"2023-09-05T08:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-invitee-a-participer-a-une-prochaine-conference-investisseur-5\/"},"modified":"2023-09-05T04:30:00","modified_gmt":"2023-09-05T08:30:00","slug":"dbv-technologies-invitee-a-participer-a-une-prochaine-conference-investisseur-5","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-invitee-a-participer-a-une-prochaine-conference-investisseur-5\/","title":{"rendered":"DBV Technologies invit\u00e9e \u00e0 participer \u00e0 une\u00a0prochaine Conf\u00e9rence Investisseur"},"content":{"rendered":"<div class=\"pr-date-globe\">September 05, 2023 16:30 ET<\/div>\n<p align=\"right\">Montrouge, France, le 5 septembre (23&nbsp;:00 CET) 2023<\/p>\n<p align=\"justify\"><strong>DBV Technologies invit\u00e9e \u00e0 participer \u00e0 une&nbsp;<\/strong><strong>prochaine<\/strong> <strong>Conf\u00e9rence Investisseur<\/strong><\/p>\n<p align=\"justify\">DBV Technologies (Euronext : DBV &#8211; ISIN : FR0010417345 &#8211; Nasdaq Stock Market : DBVT), une soci\u00e9t\u00e9 biopharmaceutique au stade clinique, a annonc\u00e9 aujourd&rsquo;hui sa participation \u00e0 la H.C. Wainwright Annual Global Investment Conference qui se tiendra du 11 au 13 septembre \u00e0 New York, NY. Daniel Tass\u00e9, directeur g\u00e9n\u00e9ral, repr\u00e9sentera la soci\u00e9t\u00e9 lors d\u2019un \u00ab&nbsp;Fireside Chat \u00bb le 12 septembre \u00e0 22h00 (16&nbsp;:00 EST), ainsi qu&rsquo;\u00e0 des rencontres individuelles avec les investisseurs tout au long de la journ\u00e9e.<\/p>\n<p align=\"justify\">La pr\u00e9sentation sera retransmise en direct sur le site web de la soci\u00e9t\u00e9, dans la section Investisseurs :<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qYZFjEdYVSmb7DaE8fIgaNWgMiCYx4r2ThQrsAsU-M9qWnnQD2sA4J9V3VAAd9OUS2bLBgLivghcXzmm0b0QPRquK1nY3uEl2-9FZXfarIHIxVzvjLDbsK7bWEQhX9kpOTrrGZQ091fvUeVIXw2FdSMt6Xdh7TJCDiMFoknfGAp9YyOvPIxVNWZyIstHK4N4kukT-5GnUrpLz-MBmvtmLw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/journey.ct.events\/view\/4f45c9c0-d6f0-4fe2-a5b2-ffc6be420349<\/a>.<\/p>\n<p align=\"justify\">L\u2019enregistrement sera \u00e9galement disponible pendant 90 jours apr\u00e8s l\u2019\u00e9v\u00e8nement&nbsp;sur le site web de DBV Technologies.<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br \/><strong>A propos de DBV Technologies<\/strong><br \/>DBV Technologies d\u00e9veloppe Viaskin\u2122, une plateforme technologique exclusive exp\u00e9rimentale avec de vastes champs d\u2019applications potentielles en immunoth\u00e9rapie. Viaskin\u2122, utilise l\u2019immunoth\u00e9rapie par voie \u00e9picutan\u00e9e, ou EPIT\u2122, qui est la m\u00e9thode d\u00e9velopp\u00e9e par DBV pour administrer des compos\u00e9s biologiquement actifs au syst\u00e8me immunitaire \u00e0 travers une peau intacte. Avec cette nouvelle cat\u00e9gorie de produits candidats non invasifs, la Soci\u00e9t\u00e9 s\u2019attache \u00e0 transformer en toute s\u00e9curit\u00e9 la prise en charge des patients souffrant d\u2019allergies alimentaires. Les programmes de DBV Technologies relatifs aux allergies alimentaires comprennent notamment des essais cliniques en cours sur Viaskin\u2122 Peanut. DBV Technologies a un si\u00e8ge social mondial \u00e0 Montrouge (France) et une structure op\u00e9rationnelle en Am\u00e9rique du Nord \u00e0 Basking Ridge, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris (mn\u00e9monique : DBV, Code ISIN : FR0010417345), tandis que les ADS de la Soci\u00e9t\u00e9 (chacune repr\u00e9sentant la moiti\u00e9 d\u2019une action ordinaire) sont n\u00e9goci\u00e9es sur le Nasdaq Global Select Market (mn\u00e9monique : DBVT).<\/p>\n<p align=\"justify\"><strong>Contact Investisseurs <\/strong><br \/>Katie Matthews<br \/>+1&nbsp;857-529-2563<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7fdhEz_mOW3FlP9jiXKNBiTBzPTzQF85X_pAT1VZ8RRdUPx8O9hRUjG1K8CwrStbdK9pRMCgm4B1aWmyrWwx8mZv0eFXIRi5mtBL-wgPdMjyINgNlj5u8jeazl-QyHInrEtdXAn-kl1eoquL4V_KiQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"katie.matthews@dbv-technologies.com\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\"><strong>Contact<\/strong> <strong>M\u00e9dia<\/strong><br \/>Angela Marcucci<br \/>DBV Technologies<br \/>+1&nbsp;646-842-2393<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yoaFt-j9AfxNIkYlZgABe2ZdGy0vIJWmNDG1k3VFTkfzVAFnNYtbB8mwZ28Ia0dEZ2WaKK8N7rJOXPKi1UntYTdPAF5BVlUWOgFS4kq1lEVD_d5TW-vHbcCh3L3qc_3K--kP6MnlHeCcv1ReC2eeEA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"angela.marcucci@dbv-technologies.com\">angela.marcucci@dbv-technologies.com<\/a>&nbsp;<\/p>\n<p align=\"justify\">Viaskin et EPIT sont des marques de DBV Technologies<\/p>\n<\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=30RHXw_hX4olJbexS-J3qCGzirkQf1hnBZbqHc2vB5i5kjlnWHQaniAFEhqRnsIc-InFMurxvpM4xZ4ovMSPi1kDUjdfCGLOJN27P55D_4YjnAhcdkRYpnTP3JUyWhP2nybWL0fKrGfM-o12oRE3U3IclS2qJe5ZRmua5_095-0=\" title=\"version PDF\" rel=\"nofollow noopener\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/N2M4NjQzYjAtNzNlMC00YzY4LWE3NTMtM2NmYjU4MTQ5NmQ0LTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">        <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-13465","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/13465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/13465\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=13465"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=13465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}